Beginning with Mizoram, the Centre on Thursday launched a Mobile Covid testing facility -- a first of its kind Mobile Diagnostic Laboratory (I-LAB) capable of performing both RT-PCR and ELISA tests -- for Northeast India.
The mobile lab has bio-safety facility and is capable of performing both RT-PCR and ELISA tests. It can also be utilised for testing other infectious diseases like TB, HIV, and therefore will remain relevant even in post-Covid times.
The Mobile Lab Technology will be rolled out gradually in other states of the Northeast as the region has unique climatic and topographical conditions.
It has been developed with support from the Department of Biotechnology (DBT) under the Ministry of Science & Technology, government of India, and is meant to provide Covid testing access to rural and remote parts of Northeast, a release from the Ministry said.
Union Minister of State for Science & Technology, Jitendra Singh, launched the mobile testing facility with Mizoram Chief Minister Pu Zoramthanga joining the ceremony online.
Exuding confidence that India will emerge triumphant from the current pandemic situation, Singh called for linking the I-LAB with a tele-consultation facility in accordance with disease profile of the population of the northeastern region.
He informed that tests like mammography and vision-testing can be added to the mobile laboratory which will prove hugely beneficial for the people of the region.
Singh said that ever since Narendra Modi took over as the Prime Minister, he has accorded special priority to the development of the Northeast, adding that this facility is a testimony of that commitment.
Acknowledging the efforts made by the AMTZ (Andhra Pradesh MedTech Zone) team for building the innovative facility, Singh said the DBT has also established manufacturing facility in AMTZ for indigenously manufacturing various healthcare technologies, which are hugely imported, thereby helping us realise the vision of 'Make-in India, Make for India'.
Speaking on the occasion, Zoramthanga said that this will help bridge the gap in Covid testing in the border districts and remote areas lacking in RT-PCR testing facilities.
--IANS
niv/arm
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)